Clopidogrel Zentiva (previously Clopidogrel Winthrop)
clopidogrel
Table of contents
Overview
This is a summary of the European public assessment report (EPAR) for Clopidogrel Zentiva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Clopidogrel Zentiva.
Authorisation details
Product details | |
---|---|
Name |
Clopidogrel Zentiva (previously Clopidogrel Winthrop)
|
Agency product number |
EMEA/H/C/000975
|
Active substance |
clopidogrel
|
International non-proprietary name (INN) or common name |
clopidogrel
|
Therapeutic area (MeSH) |
|
Anatomical therapeutic chemical (ATC) code |
B01AC04
|
Publication details | |
---|---|
Marketing-authorisation holder |
Zentiva k.s.
|
Revision |
32
|
Date of issue of marketing authorisation valid throughout the European Union |
15/07/2008
|
Contact address |
U kabelovny 130 |
Product information
23/06/2023 Clopidogrel Zentiva (previously Clopidogrel Winthrop) - EMEA/H/C/000975 - N/0087
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Antithrombotic agents
Therapeutic indication
Secondary prevention of atherothrombotic events
Clopidogrel is indicated in:
- adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;
- adult patients suffering from acute coronary syndrome:
- non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);
- ST-segment-elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.
Prevention of atherothrombotic and thromboembolic events in atrial fibrillation
In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
For further information please refer to section 5.1.